Literature DB >> 29526354

Heart Disease and Relaxin: New Actions for an Old Hormone.

Teja Devarakonda1, Fadi N Salloum2.   

Abstract

The hormone relaxin has long been recognized for its involvement in maternal adaptation during pregnancy. However, discoveries during the past two decades on the mechanism of action of relaxin, its family of receptors, and newly described roles in attenuating ischemia/reperfusion (I/R) injury, inflammation, and arrhythmias have prompted vast interest in exploring its therapeutic potential in cardiovascular disease. These observations inspired recently concluded clinical trials in patients with acute heart failure. This review discusses our current understanding of the protective signaling pathways elicited by relaxin in the heart, and highlights important new breakthroughs about relaxin signaling that may pave the way to more carefully designed future trials.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  RXFP1; fibrosis; heart failure; myocardial infarction; relaxin

Mesh：

Substances：

Year:  2018        PMID： 29526354      PMCID： PMC5911207          DOI： 10.1016/j.tem.2018.02.008

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN： 1043-2760            Impact factor:   12.015


  77 in total

1.  Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation.

Authors:  L Yue; J Feng; R Gaspo; G R Li; Z Wang; S Nattel
Journal:  Circ Res       Date:  1997-10       Impact factor: 17.367

2.  The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury.

Authors:  Øystein Sandanger; Trine Ranheim; Leif Erik Vinge; Marte Bliksøen; Katrine Alfsnes; Alexandra V Finsen; Christen P Dahl; Erik T Askevold; Geir Florholmen; Geir Christensen; Katherine A Fitzgerald; Egil Lien; Guro Valen; Terje Espevik; Pål Aukrust; Arne Yndestad
Journal:  Cardiovasc Res       Date:  2013-04-10       Impact factor: 10.787

Review 3.  Adverse Remodeling and Reverse Remodeling After Myocardial Infarction.

Authors:  Ankeet S Bhatt; Andrew P Ambrosy; Eric J Velazquez
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

4.  Combined Assessment of Relaxin and B-Type Natriuretic Peptide Improves Diagnostic Value in Patients With Congestive Heart Failure.

Authors:  Ling Han; Jingguang Luo; Shanshan Bai; Ye Jia; Xin Chen; Yan Zhao; Liwei Chen; Xiaogang Zhu; Ying Li; Yuanyuan Jiang; Xiaohong Li; Ming Yang; Dongxia Li; Xu Teng; Yongfen Qi
Journal:  Am J Med Sci       Date:  2017-07-10       Impact factor: 2.378

Review 5.  Synthetic relaxins.

Authors:  Mohammed Akhter Hossain; John D Wade
Journal:  Curr Opin Chem Biol       Date:  2014-10-01       Impact factor: 8.822

Review 6.  The inflammasome in myocardial injury and cardiac remodeling.

Authors:  Stefano Toldo; Eleonora Mezzaroma; Adolfo Gabriele Mauro; Fadi Salloum; Benjamin Wallace Van Tassell; Antonio Abbate
Journal:  Antioxid Redox Signal       Date:  2014-12-11       Impact factor: 8.401

7.  Phosphoinositide 3-kinase activity is required for biphasic stimulation of cyclic adenosine 3',5'-monophosphate by relaxin.

Authors:  Bao T Nguyen; Luping Yang; Barbara M Sanborn; Carmen W Dessauer
Journal:  Mol Endocrinol       Date:  2003-02-20

Review 8.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

9.  Nitric oxide prevents IL-1beta and IFN-gamma-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1beta-converting enzyme).

Authors:  Y M Kim; R V Talanian; J Li; T R Billiar
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

10.  Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo.

Authors:  Chrishan S Samuel; Elaine N Unemori; Ishanee Mookerjee; Ross A D Bathgate; Sharon L Layfield; John Mak; Geoffrey W Tregear; Xiao-Jun Du
Journal:  Endocrinology       Date:  2004-05-20       Impact factor: 4.736
View more
  10 in total

Review 1.  Perspectives: MRI of angiogenesis.

Authors:  Michal Neeman
Journal:  J Magn Reson       Date:  2018-04-12       Impact factor: 2.229

2.  Novel RXFP1Modulators for Treating Heart Failure.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-07-29       Impact factor: 4.632

3.  Chronic treatment with serelaxin mitigates adverse remodeling in a murine model of ischemic heart failure and modulates bioactive sphingolipid signaling.

Authors:  Teja Devarakonda; Juan Valle Raleigh; Adolfo G Mauro; Johana M Lambert; Lauren Ashley Cowart; Fadi N Salloum
Journal:  Sci Rep       Date:  2022-05-25       Impact factor: 4.996

Review 4.  G-Protein-Coupled Receptors in Heart Disease.

Authors:  Jialu Wang; Clarice Gareri; Howard A Rockman
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

Review 5.  Secretory products of the corpus luteum and preeclampsia.

Authors:  María M Pereira; Monica Mainigi; Jerome F Strauss
Journal:  Hum Reprod Update       Date:  2021-06-22       Impact factor: 15.610

Review 6.  The relaxin family peptide receptor 1 (RXFP1): An emerging player in human health and disease.

Authors:  Ting-Yun Chen; Xiaoyun Li; Ching-Hsia Hung; Harinath Bahudhanapati; Jiangning Tan; Daniel J Kass; Yingze Zhang
Journal:  Mol Genet Genomic Med       Date:  2020-02-26       Impact factor: 2.183

7.  Human Relaxin-2 Fusion Protein Treatment Prevents and Reverses Isoproterenol-Induced Hypertrophy and Fibrosis in Mouse Heart.

Authors:  Junhui Sun; Weidong Hao; Natasha Fillmore; Hanley Ma; Danielle Springer; Zu-Xi Yu; Agnieszka Sadowska; Andrew Garcia; Ruoyan Chen; Vanessa Muniz-Medina; Kim Rosenthal; Jia Lin; Denison Kuruvilla; Jane Osbourn; Sotirios K Karathanasis; Jill Walker; Elizabeth Murphy
Journal:  J Am Heart Assoc       Date:  2019-12-10       Impact factor: 5.501

8.  Cardiac Gene Therapy With Relaxin Receptor 1 Overexpression Protects Against Acute Myocardial Infarction.

Authors:  Teja Devarakonda; Adolfo G Mauro; Chad Cain; Anindita Das; Fadi N Salloum
Journal:  JACC Basic Transl Sci       Date:  2021-12-22

9.  Identification of Hub Genes of Lung Adenocarcinoma Based on Weighted Gene Co-Expression Network in Chinese Population.

Authors:  Yuning Xie; Hongjiao Wu; Wenqian Hu; Hongmei Zhang; Ang Li; Zhi Zhang; Shuhua Ren; Xuemei Zhang
Journal:  Pathol Oncol Res       Date:  2022-08-10       Impact factor: 2.874

10.  B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice.

Authors:  Teja Devarakonda; Adolfo G Mauro; Geronimo Guzman; Sahak Hovsepian; Chad Cain; Anindita Das; Praveen Praveen; Mohammed Akhter Hossain; Fadi N Salloum
Journal:  J Am Heart Assoc       Date:  2020-04-16       Impact factor: 5.501
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.